Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of Regeneron Pharmaceuticals
So what: Sales of Eylea, which launched on Nov. 21, were $24 million to $25 million in the fourth quarter, according to CEO Leonard Schleifer. He said he expects sales of Eylea in 2012 to be $140 million to $160 million.
Now what: The expected results are much higher than analysts had expected, causing the jump in shares today. Robert W. Baird analyst Christopher Raymond upgraded the stock to outperform as a result of the positive news. The results are no doubt positive, but to put this into perspective, the company's market cap is up $748 million today on the news, so I'm not jumping for joy at the stock's higher price today.
Interested in more info on Regeneron Pharmaceuticals? Add it to your watchlist by clicking here.